1. Utilization of AlphaFold models for drug discovery: Feasibility and challenges. Histone deacetylase 11 as a case study
   Fady Baselious et al, 2023, Computers in Biology and Medicine CrossRef
2. Clinicopathological Significance and Prognostic Values of Long Noncoding RNA BCYRN1 in Cancer Patients: A Meta-Analysis and Bioinformatics Analysis
   Xiaoyong Han et al, 2022, Journal of Oncology CrossRef
3. ZFP36 Inhibits Tumor Progression of Human Prostate Cancer by Targeting CDK6 and Oxidative Stress
   Dongbo Yuan et al, 2022, Oxidative Medicine and Cellular Longevity CrossRef
4. Muscleblind-like 1 antisense RNA 1 inhibits cell proliferation, invasion, and migration of prostate cancer by sponging miR-181a-5p and regulating PTEN/PI3K/AKT/mTOR signaling
   Xiang Ding et al, 2021, Bioengineered CrossRef
5. Major Role for Cellular MicroRNAs, Long Noncoding RNAs (lncRNAs), and the Epstein-Barr Virus-Encoded BART lncRNA during Tumor Growth In Vivo
   Rachel Hood Edwards et al, 2022, mBio CrossRef
6. Long Noncoding RNA Brain Cytoplasmic RNA 1 Induces Cisplatin-Resistance of Cervical Cancer Cells by Sponging MicroRNA-330-5p and Upregulating High-Mobility Group Box 3
   Dan Sun et al, 2022, Gynecologic and Obstetric Investigation CrossRef
7. Comparative Structure-Based Virtual Screening Utilizing Optimized AlphaFold Model Identifies Selective HDAC11 Inhibitor
   Fady Baselious et al, 2024, International Journal of Molecular Sciences CrossRef
8. VIM‑AS1 promotes proliferation and drives enzalutamide resistance in prostate cancer via IGF2BP2‑mediated HMGCS1 mRNA stabilization
   Sheng-Jia Shi et al, 2023, International Journal of Oncology CrossRef
9. The Pol III transcriptome: Basic features, recurrent patterns, and emerging roles in cancer
   Sihang Zhou et al, 2023, WIREs RNA CrossRef
10. Dietary stilbenes as modulators of specific miRNAs in prostate cancer
    Anait S. Levenson, 2022, Frontiers in Pharmacology CrossRef
11. HDAC11: a multifaceted histone deacetylase with proficient fatty deacylase activity and its roles in physiological processes
    Yaiza Núñez‐Álvarez et al, 2022, The FEBS Journal CrossRef
12. HDAC11: A novel target for improved cancer therapy
    Yan Liu et al, 2023, Biomedicine & Pharmacotherapy CrossRef
13. Comprehensive analysis of prognostic value and immunotherapy prospect of brain cytoplasmic RNA1 in hepatocellular carcinoma
    Xiao-Yong Han et al, 2023, World Journal of Gastrointestinal Oncology CrossRef
14. Epigenetic regulation in cancer therapy: From mechanisms to clinical advances
    Lei Tao et al, 2024, MedComm – Oncology CrossRef
15. BCYRN1: An oncogenic lncRNA in diverse cancers
    Soudeh Ghafouri-Fard et al, 2021, Pathology - Research and Practice CrossRef
16. Exploration of drug resistance mechanisms in triple negative breast cancer cells using a microfluidic device and patient tissues
    Wanyoung Lim et al, 2024, eLife CrossRef
17. miRNA and lncRNA Expression Networks Modulate Cell Cycle and DNA Repair Inhibition in Senescent Prostate Cells
    Willian A. da Silveira et al, 2022, Genes CrossRef
18. MSF-UBRW: An Improved Unbalanced Bi-Random Walk Method to Infer Human lncRNA-Disease Associations
    Lingyun Dai et al, 2022, Genes CrossRef
19. Exploration of drug resistance mechanisms in triple negative breast cancer cells using a microfluidic device and patient tissues
    Wanyoung Lim et al, 2024, eLife CrossRef
20. miR-939, as an important regulator in various cancers pathogenesis, has diagnostic, prognostic, and therapeutic values: a review
    Hosein Kouchaki et al, 2024, Journal of the Egyptian National Cancer Institute CrossRef